Table 4 Cox regression model analysis of overall survival in patients with early-stage and advanced-stage epithelial ovarian cancer
From: Identification and clinical validation of NUSAP1 as a novel prognostic biomarker in ovarian cancer
Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
HR | 95%Â CI of HR | P-value | HR | 95%Â CI of HR | P-value | |
Early-stage epithelial ovarian cancer | ||||||
  NUSAP1 expression (low vs. high) | 12.697 | 1.587–101.576 | 0.017* | 9.522 | 1.064–85.252 | 0.044* |
  Age (years) (< 60 vs. ≥ 60) | 2.046 | 0.575–7.290 | 0.269 | 1.451 | 0.395–5.337 | 0.575 |
  Tumor grade (1–2 vs. 3) | 1.708 | 0.493–5.914 | 0.398 | 0.859 | 0.216–3.411 | 0.829 |
  Lymph node metastasis (no vs. yes) | - | - | - | - | - | - |
  Residual tumor size (≤ 1 cm vs. > 1 cm) | - | - | - | - | - | - |
  Pathological subtype (nonserous vs. serous) | 29.281 | 0.044–19,460.028 | 0.308 | 111,520.722 | 0.000–3.960E + 258 | 0.969 |
Advanced-stage epithelial ovarian cancer | ||||||
  NUSAP1 expression (low vs. high) | 2.223 | 0.511–9.664 | 0.287 | 2.234 | 0.471–10.585 | 0.311 |
  Age (years) (< 60 vs. ≥ 60) | 1.621 | 0.670–3.920 | 0.284 | 2.262 | 0.876–5.839 | 0.092 |
  Tumor grade (1–2 vs. 3) | 1.022 | 0.415–2.517 | 0.963 | 0.821 | 0.282–2.394 | 0.718 |
  Lymph node metastasis (no vs. yes) | 1.013 | 0.402–2.552 | 0.979 | 1.093 | 0.417–2.867 | 0.857 |
  Residual tumor size (≤ 1 cm vs. > 1 cm) | 4.894 | 1.503–15.940 | 0.008* | 4.604 | 1.371–15.466 | 0.014* |
  Pathological subtype (nonserous vs. serous) | 1.747 | 0.723–4.223 | 0.215 | 1.982 | 0.698–5.629 | 0.199 |